Table 1.
Model | Findings | Ref |
---|---|---|
Transgenic mice | ||
AC6 | No change in basal cAMP production and LV function; increased LV function in response to βAR stimulation | 39 |
AC6 | Facilitation of atrioventricular nodal conduction without altering sinus node function | 68 |
AC6 and acute MI | Reduced mortality in acute MI; improved SR Ca2+ uptake; normalized PLB phosphorylation | 50 |
AC6 and MI | Decreased fibrosis and increased engraftment of iPS cells in the infarcted area | 51 |
AC6 × Gαq | Restored cAMP generation capacity; increased LV function and βAR responsiveness | 44 |
AC6 × Gαq | Decreased LV hypertrophy, increased LV function and prolonged survival in Gαq cardiomyopathy | 45 |
AC6 × Gαq | Normalized LV SR Ca2+ uptake and PLB phosphorylation in Gαq cardiomyopathy | 48 |
AC6 × Gαq | No alteration in heart rate regulation | 47 |
AC6 × Gαq | Corrects prolonged action potential duration in Gαq cardiomyopathy | 49 |
AC6-tet | Increased LV responsiveness to βAR stimulation after activation of cardiac-directed AC6 expression | 40 |
AC6-tet in CHF | Increased LV function of failing heart (CHF induced by MI); normalized cTnI phosphorylation | 3 |
AC6-tet and aging | Improved Ca2+ handling and increased LV function in mice aged 24 months, but not in young mice | 57 |
AC6 deletion | Marked adverse effects on Ca2+ uptake; reduced LV function in response to βAR stimulation | 37 |
Gene transfer in cells | ||
NRCM | AC6 amount determines NRCM response to βAR stimulation | 38 |
NRCM | AC6 reduces PLB expression by increasing ATF3 content through cAMP-independent pathway | 58 |
NRCM | AC6 increases PLB phosphorylation by activating Akt (cAMP independent) | 60 |
NRCM | AC6 regulates Akt activity in NRCM (cAMP independent) | 59 |
NRCM | AC6 vs β1AR: differences in intracellular distribution—an important determinant of biological effects | 69 |
ARCM | AC6 and AC6mut (catalytically inactive) have similar benefits in ARCM | 70 |
In vivo gene transfer | ||
C57BL/6 mouse | Indirect intracoronary delivery of Ad.AC6: increased LV function in response to βAR stimulation | 31 |
Gαq mouse | Intracoronary delivery of Ad.AC6: increased LV function in Gαq cardiomyopathy | 46 |
Normal pig | Intracoronary delivery of Ad.AC6: increased LV function in response to βAR stimulation | 41 |
CHF pig | Intracoronary delivery of Ad.AC6: increased function of failing LV | 42 |
Normal pig | Intracoronary delivery of Ad.AC6: persisted cardiac AC6 expression for 10 weeks without toxicity | —a |
Abbreviations: AC6, adenylyl cyclase 6; ARCM, adult rat cardiac myocytes; ATF3, activating transcription factor 3; βAR, β-adrenergic receptor; cAMP, 3′,5′-cyclic adenine monophosphate; CHF, congestive heart failure; cTnI, cardiac troponin I; iPS cells, induced pluripotent stem cells; LV, left ventricular; MI, myocardial infarction; NRCM, neonatal rat cardiac myocytes; PLB, phospholamban; SR, sarcoplasmic reticulum.
Food and Drug Administration (FDA) Investigational New Drug (IND) application.